Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.

Vivani Medical, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

THE COMPANY EXPECTS TO REESTABLISH AND ANNOUNCE A NEW RECORD DATE AS SOON AS POSSIBLE THE COMPANY EXPECTS TO REESTABLISH AND ANNOUNCE A NEW RECORD DATE AS SOON AS POSSIBLE

VIVANI MEDICAL WITHDRAWS RECORD DATE FOR CORTIGENT NEUROMODULATION SUBSIDIARY SPIN-OFF

ALAMEDA, CALIF., SEPT. 24, 2025 (GLOBE NEWSWIRE) -- VIVANI MEDICAL, INC. (NASDAQ: VANI) (VIVANI OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MINIATURE, ULTRA LONG-ACTING DRUG IMPLANTS, TODAY ANNOUNCED THAT IT WILL PRESENT AT THE EMERGING GROWTH CONFERENCE 86 ON SEPTEMBER 25, 2025.

VIVANI MEDICAL TO PRESENT AT THE EMERGING GROWTH CONFERENCE ON SEPTEMBER 25, 2025

CORTIGENT IS A LEADING DEVELOPER OF BRAIN IMPLANT DEVICES BASED ON PRECISION NEUROSTIMULATION TECHNOLOGY. IT IS THE ONLY COMPANY TO HAVE OBTAINED FDA APPROVAL OF A DEVICE PROVIDING ARTIFICIAL VISION FOR THE PROFOUNDLY BLIND

VIVANI MEDICAL ANNOUNCES RECORD DATE FOR SPIN-OFF OF CORTIGENT NEUROMODULATION SUBSIDIARY TO SHAREHOLDERS

NPM-139 HAS POTENTIAL TO PROVIDE WEGOVY-LEVEL EFFICACY WITH ONCE OR TWICE-YEARLY ADMINISTRATION FIRST-IN-HUMAN PHASE 1 STUDY IS EXPECTED TO INITIATE IN THE FIRST HALF OF 2026, PENDING REGULATORY CLEARANCE PREPARATIONS FOR DOSE-RANGING PHASE 2 STUDY OF NPM-139 TO OCCUR IN PARALLEL WITH PHASE 1 STUDY ALAMEDA, CALIF., SEPT. 04, 2025 (GLOBE NEWSWIRE) -- VIVANI MEDICAL, INC. (NASDAQ: VANI) (VIVANI OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, ULTRA LONG-ACTING DRUG IMPLANTS, TODAY ANNOUNCED PLANS TO INITIATE A PHASE 1 CLINICAL STUDY IN THE NPM-139 SEMAGLUTIDE IMPLANT PROGRAM IN THE FIRST HALF OF 2026, PENDING REGULATORY CLEARANCE.

VIVANI MEDICAL PROVIDES UPDATE ON CLINICAL DEVELOPMENT PLANS FOR NPM-139 SEMAGLUTIDE IMPLANT FOR CHRONIC WEIGHT MANAGEMENT

ALAMEDA, CALIF., AUG. 20, 2025 (GLOBE NEWSWIRE) -- VIVANI MEDICAL, INC. ( NASDAQ: VANI ) (VIVANI OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MINIATURE, ULTRA LONG-ACTING DRUG IMPLANTS, ANNOUNCED TODAY THAT CEO ADAM MENDELSOHN, PH.D., WILL PRESENT A COMPANY OVERVIEW AND CONDUCT PARTNERING MEETINGS AT THE H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE, TAKING PLACE FROM SEPTEMBER 8-10, 2025 IN NEW YORK, NEW YORK.

VIVANI MEDICAL CEO ADAM MENDELSOHN TO PRESENT AT THE H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE ON SEPTEMBER 10, 2025

COMPANY PLANS RAPID ADVANCEMENT OF SEMAGLUTIDE IMPLANT NPM-139, FOLLOWING POSITIVE WEIGHT LOSS DATA FROM AN ONGOING PRECLINICAL STUDY OF NPM-139 AND PROMISING RESULTS FROM THE LIBERATE-1 PHASE 1 CLINICAL STUDY OF NPM-115

VIVANI MEDICAL PROVIDES BUSINESS UPDATE INCLUDING $10M EQUITY FINANCING AND REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

ALL SUBJECTS IN THE NPM-115 COHORT HAD SUCCESSFUL INSERTIONS OF A MINIATURE, ULTRA LONG-ACTING GLP-1 (EXENATIDE) IMPLANT IN THE ON-GOING LIBERATE-1 STUDY IN OBESE OR OVERWEIGHT INDIVIDUALS; TOP-LINE RESULTS ARE ANTICIPATED IN MID-2025

VIVANI MEDICAL PROVIDES BUSINESS UPDATE INCLUDING $3M EQUITY FINANCING AND REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

ALAMEDA, CALIF., MAY 07, 2025 (GLOBE NEWSWIRE) -- VIVANI MEDICAL, INC. (NASDAQ: VANI) (THE COMPANY OR VIVANI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MINIATURE, ULTRA LONG-ACTING DRUG IMPLANTS, ANNOUNCED TODAY THAT CEO ADAM MENDELSOHN, PH.D., WILL PRESENT AND PARTICIPATE IN A PANEL DISCUSSION AT THE AMERICAN ASSOCIATION OF PHARMACEUTICAL SCIENTISTS' (AAPS) BEYOND GLP1S: WHERE THE SCIENCE WILL TAKE BUSINESS NEXT VIRTUAL WORKSHOP, TAKING PLACE FROM MAY 13-14, 2025.

VIVANI MEDICAL TO PRESENT AT THE AMERICAN ASSOCIATION OF PHARMACEUTICAL SCIENTISTS' BEYOND GLP1S: WHERE THE SCIENCE WILL TAKE BUSINESS NEXT VIRTUAL WORKSHOP

OVER HALF OF ALL DOGS IN THE UNITED STATES TODAY ARE OVERWEIGHT OR OBESE, PLACING THEM AT INCREASED RISK FOR CHRONIC DISEASES, METABOLIC DECLINE AND SHORTENED LIFESPANS OVER HALF OF ALL DOGS IN THE UNITED STATES TODAY ARE OVERWEIGHT OR OBESE, PLACING THEM AT INCREASED RISK FOR CHRONIC DISEASES, METABOLIC DECLINE AND SHORTENED LIFESPANS

VIVANI MEDICAL AND OKAVA EXPAND COLLABORATION TO DEVELOP OKV-119 FOR DOGS, TARGETING METABOLIC HEALTH AND LONGEVITY

SUCCESSFUL INITIAL ADMINISTRATION AND FULL ENROLLMENT IN FIRST-IN-HUMAN LIBERATE-1  STUDY OF NPM-115 (EXENATIDE IMPLANT) IN OBESE AND OVERWEIGHT SUBJECTS WITH TOP-LINE DATA EXPECTED IN MID-2025

Vivani Medical, Inc.

VANI

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Vivani Medical, Inc.

VANI.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

VANI